Work Here?
Adaptive Biotechnologies
Work Here?
Decodes immune cell genetic information for diagnostics
Adaptive Biotechnologies
Work Here?
Decodes immune cell genetic information for diagnostics
About Adaptive Biotechnologies
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Total Funding
$395.8M
Headquarters
Seattle, Washington
Founded
2009
Overview
Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand how the immune system reacts to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to advance healthcare by leveraging immune system data to develop better therapies and diagnostic tools.
Simplify's Take
What believers are saying
- Strong investor confidence with investments from firms like Jacobs Levy and Acadian Asset Management.
- Partnership with EndoSound could expand product offerings in the medical device market.
- Recognition as Workplace of the Year highlights a strong company culture attracting top talent.
What critics are saying
- Emerging competition from startups like Adaptive with $20 million funding for AI applications.
- Regulatory hurdles in developing new medical devices with EndoSound partnership.
- Pressure from investors for rapid financial returns may impact long-term R&D.
What makes Adaptive Biotechnologies unique
- Adaptive Biotechnologies leverages immune system data for disease diagnosis and treatment.
- Their clonoSEQ test is FDA-authorized for monitoring minimal residual disease in blood cancers.
- The ImmuneRACE study enhances understanding of immune responses to COVID-19.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$395.8M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Company Equity
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -3%2 year growth
↑ 2%SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.About Adaptive BiotechnologiesAdaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease
Jacobs Levy Equity Management Inc. makes new $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).
"We are inspired to see clonoSEQ MRD testing featured in a record-breaking number of studies at this year's ASH Annual Meeting," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies.
Canada Pension Plan Investment Board makes new $98,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT).
Acadian Asset Management LLC invests $519,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT).
Adaptive Biotechnologies is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Adaptive Biotechnologies
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Total Funding
$395.8M
Headquarters
Seattle, Washington
Founded
2009
Adaptive Biotechnologies is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today